AstraZeneca's $1 Billion Acquisition of EsoBiotec

Deal Overview

• Acquirer: AstraZeneca PLC

• Target: EsoBiotec SA

• Total Transaction Value: Up to $1 billion (cash and debt free)

• Transaction Structure: $425 million upfront at closing; up to $575 million in contingent consideration tied to development and regulatory milestones

• Public Announcement Date: 17 March 2025

• Closing Date: 20 May 2025

• Post-Closing Structure: EsoBiotec operates as a wholly owned subsidiary of AstraZeneca, retaining operations in Belgium Summary AstraZeneca's acquisition of EsoBiotec is a bet on the next generation of cancer immunotherapy.

AstraZeneca's acquisition of EsoBiotec is a bet on the next generation of cancer immunotherapy. The deal comes as the CAR-T cell therapy market faces increasing pressure over prohibitive costs and weeks-long manufacturing timelines. EsoBiotec's proprietary Engineered NanoBody Lentiviral (ENaBL) platform offers a potential shift through its in vivo reprogramming of T cells delivered via a simple IV injection in minutes. For AstraZeneca, which has set an ambitious target of $80 billion in revenue by 2030 and already holds seven cell therapy programmes in the clinic, this acquisition accelerates entry into the off-the-shelf in vivo space, extending the strategic momentum of its earlier Gracell Biotechnologies purchase in 2023. The principal legal consideration is not antitrust scrutiny, which was minimal given EsoBiotec's pre-clinical-stage profile, but rather the novel and unsettled regulatory landscape governing in vivo gene-modified cell therapies.

Company Details: Acquirer

After the pandemic, AstraZeneca needs little introduction. Founded in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group, AstraZeneca is a global biopharmaceutical company headquartered in Cambridge, UK. It operates across three core therapeutic areas in Oncology, Rare Diseases, and BioPharmaceuticals (which encompasses Cardiovascular, Renal and Metabolism and Respiratory and Immunology), and is classified within the large-cap pharmaceutical and biotechnology sector. At the time of the EsoBiotec deal, it was the largest company by market capitalisation on the London Stock Exchange, valued at approximately $185 billion.

AstraZeneca's publicly stated mission is to push the boundaries of science to deliver life-changing medicines, with a particular ambition to eliminate cancer as a cause of death. This science-led, patient-centred, and commercially aggressive ethos has defined the company's identity under CEO Pascal Soriot, who has led AstraZeneca since 2012. Soriot's tenure is itself one of the most significant strategic turnarounds in modern pharmaceutical history. When he arrived, AstraZeneca was facing a severe patent cliff, with blockbusters including Crestor (rosuvastatin) and Seroquel (quetiapine) losing exclusivity and revenues declining sharply. The company had also rejected a $118 billion hostile takeover bid from Pfizer in 2014, one of the largest attempted pharma acquisitions ever, a decision Soriot defended on the basis that AstraZeneca's pipeline was undervalued by the market.

The response to these pressures was a wholesale strategic pivot. AstraZeneca exited commoditised therapeutic areas and concentrated R&D investment in high-value oncology, rare disease, and biologics. This shift was enabled by a series of transformative partnerships and acquisitions. Key early moves included the 2015 immuno-oncology collaboration with MedImmune (which AstraZeneca had acquired in 2007 for $15.6 billion), the co-development deal with Daiichi Sankyo for the antibody-drug conjugate Enhertu, and the landmark $39 billion acquisition of Alexion Pharmaceuticals in 2021, the largest in the company's history, which established AstraZeneca as a leader in rare disease through Alexion's complement inhibitor franchise including Soliris and Ultomiris.

AstraZeneca's core product strengths at the time of the deal included Tagrisso (osimertinib) for EGFR-mutated non-small cell lung cancer, its single largest product with sales exceeding $5 billion annually, alongside Enhertu (fam-trastuzumab deruxtecan), Imfinzi (durvalumab), Calquence (acalabrutinib), Farxiga (dapagliflozin) in cardiovascular disease, and the rare disease portfolio inherited from Alexion. The company reported total revenue of $54.07 billion in 2024, representing 21% year-on-year growth, with oncology now approximately 43% of total revenue driving a 24% increase. These results were not merely a product of existing blockbusters but reflected the company's evolving pipeline philosophy, moving from small molecules to biologics, antibody-drug conjugates, and increasingly cell and gene therapies. AstraZeneca operates in more than 125 countries and is pursuing an "Ambition 2030" strategy targeting $80 billion in total revenue, underpinned by the planned launch of roughly 20 new medicines.

In terms of its competitive environment, AstraZeneca sits alongside Pfizer, Merck (MSD), Bristol Myers Squibb, Novartis, and Roche as the dominant forces in global oncology. In the cell therapy subsector specifically, it competes with Novartis (Kymriah, plus in vivo CAR-T investments through Vyriad), Gilead/Kite (Yescarta, Tecartus), and BMS (Breyanzi, Abecma) in approved ex vivo products, while racing against Umoja Biopharma, Interius BioTherapeutics, and others in the emerging in vivo space. The EsoBiotec acquisition is a direct response to this competitive dynamic. AstraZeneca had publicly expressed interest in in vivo cell therapy as far back as 2022 but acknowledged persistent technical barriers around lentiviral vector stability in peripheral circulation. Those barriers appeared to dissolve when EsoBiotec's early clinical data from the first patient dosed with ESO-T01 was presented at the JP Morgan Healthcare Conference in January 2025, prompting rapid negotiations and, within two months, a signed and publicly announced deal.

Company Details: Target

EsoBiotec is a privately held Belgian biotechnology company founded in 2020 and headquartered in Mont-Saint-Guibert, Belgium, in the Walloon region. It is classified within the cell and gene therapy subsector of the biotechnology industry. The company was founded by Jean-Pierre Latere, PhD, who remained CEO at the time of the acquisition. Motivated by personal experience with cancer in his family and professional frustration with the cost and access barriers of existing CAR-T therapies, Latere founded EsoBiotec with an explicit mission to make in vivo cell therapies more accessible, more effective, and genuinely affordable. As a privately held pre-revenue company, EsoBiotec had no conventional market valuation prior to the deal. The acquisition consideration of up to $1 billion, against total fundraising of just €22 million, implies an extraordinary return on invested capital and reflects the strategic premium AstraZeneca placed on the ENaBL platform's potential.

EsoBiotec's sole asset is its proprietary ENaBL (Engineered NanoBody Lentiviral) platform. This third-generation immune-shielded lentiviral vector technology is designed to reprogram T cells directly within the patient's body, eliminating the need for ex vivo cell harvesting, genetic modification, and reinfusion. Unlike traditional autologous CAR-T production, which typically takes two to six weeks, requires specialised apheresis centres, involves hospitalisation for lymphodepletion, and costs between $373,000 and $475,000 per patient, ENaBL-based therapies are intended to be delivered via a simple IV injection in approximately ten minutes, without lymphodepletion. By the time of the acquisition, the ENaBL platform had reached its third generation, incorporating immune shielding features designed to reduce immune rejection and graft-versus-host disease risk.

The company's lead programme, ESO-T01, targets the BCMA antigen for the treatment of multiple myeloma. It is notable as the first in vivo BCMA CAR-T candidate to enter clinical trials anywhere in the world, with an investigator-initiated trial launched in December 2024 in partnership with China's Shenzhen Pregene Biopharma. A key milestone was the dosing of the first patient and the presentation of those results, showing strong cell kinetics, at the JP Morgan Healthcare Conference in January 2025. AstraZeneca's head of oncology R&D, Susan Galbraith, described the data as demonstrating "really quite impressive cell kinetics," and it was this single data point that directly catalysed the acquisition. This trajectory, from founding to first-in-human data to a billion-dollar acquisition in roughly four years, is impressive by the standards of the sector and reflects both the quality of the underlying science and the capital efficiency of Latere's approach.

EsoBiotec operated in a competitive environment that, while nascent, was rapidly attracting well-capitalised players. Umoja Biopharma, Interius BioTherapeutics, and Sana Biotechnology were all pursuing in vivo cell therapy strategies in parallel, with several raising hundreds of millions in venture capital against EsoBiotec's €22 million. EsoBiotec's strategic response to this resource disparity was not to compete for capital but to move faster, focusing relentlessly on the ENaBL platform, achieving first-in-human proof-of-concept ahead of better-funded peers, and selecting a development partner in China to run an investigator-initiated trial efficiently and generate early clinical data without the costs of a sponsored Phase I trial. This approach effectively compressed the company's pathway to acquisition-readiness and positioned it advantageously when AstraZeneca was looking to move quickly. Prior to the AstraZeneca deal, EsoBiotec had not undertaken any material mergers or acquisitions, its strategic development being entirely organic, funded by its founding investors and regional investment bodies. This included Wallonie Entreprendre, a public Walloon regional investment agency whose co-investment reflects the broader Belgian public interest in the company's success and the subsequent questions about whether a publicly subsidised innovation will remain accessible once commercialised by a global pharmaceutical acquirer.

The Acquisition Timeline

• January 2025: EsoBiotec presents first clinical data from ESO-T01 at the JP Morgan Healthcare Conference, prompting AstraZeneca's interest

• 17 March 2025: Definitive agreement announced

• 20 May 2025: Acquisition completed; EsoBiotec becomes a wholly owned subsidiary of AstraZeneca

• Milestone structure: Up to $575 million in future payments contingent on clinical development and regulatory approvals

Motivation

For AstraZeneca, the acquisition serves several strategic purposes. First, it provides a platform advantage. By owning ENaBL outright, AstraZeneca can cross-apply learnings from its existing autologous programmes to the in vivo format at scale, rather than being locked into licensing arrangements. Second, there is a compelling cost and access argument. Current approved CAR-T therapies cost between $373,000 and $475,000 per patient, with substantial additional hospitalisation costs. ENaBL's off-the-shelf, manufacturing-light design could significantly reduce this, aligning with AstraZeneca's stated ambition to widen patient access. Third, the timing was strategically sound. EsoBiotec was acquired before it had accumulated the valuations of comparable competitors who raised hundreds of millions before being acquired, giving AstraZeneca a relatively capital-efficient entry point into the technology. For EsoBiotec, AstraZeneca represented not only the highest bidder but, in Latere's words, the best strategic fit. It is a European company that understands cell therapy, is attuned to access and cost concerns, and committed to maintaining EsoBiotec's identity and Belgian presence.

Integration

Under the deal terms, EsoBiotec continues to operate as a distinct entity within AstraZeneca, retaining its Belgian headquarters and its founding CEO Jean-Pierre Latere. This reflects a deliberate integration approach common in platform-technology acquisitions. It allows EsoBiotec to preserve its scientific culture and operational continuity while providing access to AstraZeneca's global clinical, regulatory, and commercial infrastructure. The ENaBL platform will be developed in tandem with AstraZeneca's existing cell therapy pipeline, including CAR-T, TCR-T, and CAR Treg programmes, allowing the company to hedge across ex vivo and in vivo modalities. AstraZeneca confirmed the deal has no impact on its 2025 financial guidance. Legal representation is notably distinguished. AstraZeneca was advised by Covington & Burling, a firm that has guided several of the company's prior acquisitions, including the $1.8 billion CinCor deal. EsoBiotec was represented by Cooley LLP, with a cross-border team spanning San Diego (M&A and licensing partners) and London (M&A and life sciences). Centerview Partners acted as EsoBiotec's exclusive financial advisor.

Legal Contentions & Regulatory Impact

Legal & Regulatory Issues

The EsoBiotec transaction closed without significant merger control challenges. Given that EsoBiotec had no approved products, no material revenues, and minimal market presence, the deal was unlikely to raise substantive horizontal competition concerns before the European Commission, the UK Competition and Markets Authority (CMA), or the US Department of Justice/Federal Trade Commission (DOJ/FTC). The deal closed in approximately two months from announcement to completion, consistent with a transaction subject only to customary closing conditions rather than in-depth antitrust review. The more substantial and enduring legal question concerns the regulatory framework governing ENaBL itself. In vivo gene-modified cell therapies represent a novel drug class that sits at the intersection of cell therapy and gene therapy regulation. Unlike the seven FDA-approved ex vivo CAR-T products, all of which proceeded through the Biologics License Application (BLA) pathway supported by single-arm trial data, in vivo CAR-T therapies will face an evolving and increasingly demanding regulatory standard. In December 2025, FDA Biologics Chief Vinay Prasad published new guidance signalling that future CAR-T approvals should generally be supported by randomised controlled trials demonstrating superiority over standard of care, rather than single-arm studies. This marks a significant escalation in the evidentiary bar, and while this guidance applies broadly to the CAR-T field, it carries particular weight for in vivo programmes given their earlier-stage clinical development. In Europe, EsoBiotec's technology falls under the Advanced Therapy Medicinal Products (ATMP) Regulation (EC No 1394/2007), which governs gene therapies, somatic cell therapies, and tissue-engineered products. The European Medicines Agency (EMA) has offered an accelerated pathway for innovative ATMPs through its PRIME scheme, though the regulatory burden for novel vector-based products remains considerable. A further regulatory risk specific to lentiviral-vector-based in vivo therapies concerns insertional oncogenesis. Because ENaBL uses integrating lentiviral vectors, regulators, including the FDA, will expect sponsors to demonstrate that transduction is targeted specifically to T cells and not to haematopoietic stem cells or other off-target populations. This is a higher bar than for approved ex vivo lentiviral products (such as Novartis's Kymriah or bluebird bio's Zynteglo), because the vector is administered systemically rather than to cells that have been isolated and characterised ex vivo.

Impact on Transaction Value

The milestone-heavy payment structure ($425 million upfront; $575 million contingent) reflects the deal parties' shared recognition that the primary risk in the transaction is not competition law but regulatory and clinical execution. The substantial contingent component effectively transfers much of the financial risk to post-approval milestones, aligning AstraZeneca's payment obligations with validated clinical and regulatory progress. This is consistent with standard practice in early-stage biotechnology acquisitions and provides AstraZeneca downside protection if ENaBL's promising early data does not translate through Phase II/III trials. Industry analysts have projected that the first ENaBL-derived product could reach the market within five to six years, meaning the full $1 billion consideration will likely not be triggered until the early 2030s at the earliest.

Deal Implications

The rapid and uncontested regulatory clearance of this deal reflects a broader enforcement trend. Competition authorities have generally declined to challenge pre-revenue platform-technology acquisitions in the pharmaceutical sector, reserving scrutiny for deals involving overlapping approved products or near-term pipeline competitors. This stands in some contrast to the CMA's investigation of AstraZeneca's much larger $39 billion Alexion acquisition in 2021, which involved approved rare disease products. Separately, the growing FDA emphasis on randomised trial designs for CAR-T approvals, applied on a product-by-product basis, may compound regulatory risk post-closing if ESO-T01 or successor programmes are required to fund and execute large, multi-arm pivotal studies. This could extend the timeline to commercialisation and increase development costs, potentially affecting the probability of triggering the full milestone payments.

Industry Impact

The EsoBiotec acquisition is one of the clearest signals yet that the cell therapy industry is entering a new phase, characterised by a pivot away from expensive, logistically intensive ex vivo autologous therapies toward scalable, off-the-shelf in vivo platforms. This transition has implications across several dimensions. On cost and access, approved ex vivo CAR-T therapies remain out of reach for the majority of global patients, with treatment costs that have drawn Congressional scrutiny in the US and recurring criticism from payers and patient advocates. ENaBL's off-the-shelf design, if validated clinically, could be among the first technologies to address this structural barrier in a meaningful way. On competitive dynamics, AstraZeneca now joins Novartis (which acquired Vyriad's lentiviral vector platform) and Umoja Biopharma (whose UB-VV111 has received FDA Fast Track designation for B-cell malignancies) in the in vivo CAR-T race. The field is emerging and intensifying, and AstraZeneca's acquisition of what is arguably the most advanced in vivo BCMA programme, already in clinical trial, gives it a meaningful head start in the haematology space. On workforce and manufacturing, ENaBL's approach could significantly alter the economics of cell therapy production. A therapy administered in minutes rather than weeks eliminates the need for specialised apheresis centres, ex vivo manufacturing suites, and the complex cold-chain logistics currently required by approved CAR-T products. This has positive implications for patient access in lower-resource settings but will also disrupt existing manufacturing infrastructure built around ex vivo processes.

House View

The AstraZeneca-EsoBiotec deal is strategically coherent and financially measured. By acquiring ENaBL at an upfront price of $425 million, (remarkable given EsoBiotec's €22 million total funding history), AstraZeneca has secured what could become a foundational platform in next-generation cell therapy at a cost well below that of comparable platform acquisitions. The deal deepens AstraZeneca's cell therapy portfolio at a critical juncture. The company's existing ex vivo CAR-T programme is advancing in multiple myeloma and lupus, and ENaBL's modular in vivo design is well-positioned to apply the same BCMA and CD19 targeting insights to a scalable, off-the-shelf format. That said, material risks remain. Clinically, ENaBL is at the earliest possible stage, and first-in-human data from a single patient is promising but far from pivotal. The challenge of demonstrating durable CAR-T expansion from an in vivo vector, particularly in solid tumours where the immunosuppressive tumour microenvironment poses persistent barriers, has not yet been addressed. Regulatory risks are also compounding. The FDA's emerging preference for randomised superiority trials will place significant demands on AstraZeneca's clinical development programme for ESO-T01 and successor compounds, potentially delaying and increasing the cost of approval. The EMA's ATMP pathway, while accommodating, similarly requires extensive long-term safety data for integrating vector technologies, particularly around insertional mutagenesis monitoring. From a public policy perspective, the deal raises questions about whether a technology developed by a capital-constrained start-up with public sector co-investment can, once commercialised by a large pharmaceutical acquirer, realistically fulfil the patient access promise that motivated its creation. AstraZeneca's track record on access commitments following major acquisitions, including Alexion and Gracell, will be closely watched by payers and regulators. The broader in vivo CAR-T sector is approaching a defining inflection point. If ESO-T01's Phase I data in China translates into robust efficacy and manageable safety in larger international trials, AstraZeneca will be extremely well positioned. If not, the contingent milestone structure provides meaningful financial protection, but the strategic gap in AstraZeneca's next-generation cell therapy pipeline may prove difficult and expensive to fill.

References

AstraZeneca (2025) AstraZeneca to acquire EsoBiotec to advance cell therapy ambition. Available at: https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-to-acquire-esobiot ec.html

AstraZeneca (2025) Acquisition of EsoBiotec completed. Available at: https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2025/acquisition-of-es obiotec-completed.html

AstraZeneca (2026) Full-year and Q4 2025 results announcement. Available at: https://www.astrazeneca.com/content/dam/az/PDF/2025/Q4-FY/Full-year-Q4-2025-results-anno uncement.pdf

AstraZeneca (2025) 9M and Q3 2025 results announcement. Available at: https://www.astrazeneca.com/content/dam/az/PDF/2025/9m-q3/9M-and-Q3-2025-results-annou ncement.pdf

AstraZeneca (2025) AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO. Available at: https://www.astrazeneca-us.com/media/press-releases/2025/AstraZeneca-furthers-ambition-to-r edefine-cancer-care-with-first-data-from-four-major-pivotal-trials-at-ESMO.html

BioPharm International (2025) AstraZeneca to acquire EsoBiotec, boosting cell therapy portfolio. Available at: https://www.biopharminternational.com/view/astrazeneca-acquire-esobiotec-boosting-cell-therap y-portfolio

BioPharm International (2026) Technology for in vivo CAR T-cell therapy advances. Available at: https://www.biopharminternational.com/view/technology-for-in-vivo-car-t-cell-therapy-advances

BioPharma Dive (2024) AstraZeneca's $80B sales plan leans on cancer drug expansion. Available at: https://www.biopharmadive.com/news/astrazeneca-2030-goal-cancer-drugs-oncology-strategy/7 16756/

BioSpace (2025) AstraZeneca makes potential $1B cell therapy play in EsoBiotec buy. Available at: https://www.biospace.com/business/astrazeneca-makes-potential-1b-cell-therapy-play-in-esobio tec-buy

BioSpace (2025) EsoBiotec to be acquired by AstraZeneca to advance cell therapy ambition. Available at: https://www.biospace.com/press-releases/esobiotec-to-be-acquired-by-astrazeneca-to-advancecell-therapy-ambition

Bloomberg (2025) AstraZeneca to buy Belgian cell therapy firm EsoBiotec for up to $1 billion. Available at: https://www.bloomberg.com/news/articles/2025-03-17/astrazeneca-to-buy-cell-therapy-company -for-up-to-1-billion

Born2Invest (2025) AstraZeneca acquired biotech company EsoBiotec for one billion dollars. Available at: https://born2invest.com/articles/astrazeneca-acquired-biotech-esobiotec/

CBInsights (2025) EsoBiotec company profile. Available at: https://www.cbinsights.com/company/esobiotec

Clinical Trials Arena (2025) FDA's latest CGT guidance streamlines path for in vivo CAR-T development. Available at: https://www.clinicaltrialsarena.com/interviews/fdas-latest-cgt-guidance-streamlines-path-for-in-vi vo-car-t-development/

Cooley LLP (2025) EsoBiotec announces up to $1 billion acquisition by AstraZeneca. Available at: https://www.cooley.com/news/coverage/2025/2025-03-17-esobiotec-announces-up-to-$1-billionacquisition-by-astrazeneca

Covington and Burling LLP (2025) Covington advises AstraZeneca in its acquisition of EsoBiotec. Available at: https://www.cov.com/news-and-insights/news/2025/03/covington-advises-astrazeneca-in-its-acq uisition-of-esobiotec

EsoBiotec (2024) EsoBiotec begins clinical trial of in vivo BCMA CAR-T candidate ESO-T01 for multiple myeloma. Available at: https://www.esobiotec.com/press-release-investigator-initiated-trial/

EsoBiotec (2025) Company website. Available at: https://www.esobiotec.com/

Fierce Biotech (2025) AstraZeneca goes in vivo, penning $1B deal for Belgian off-the-shelf cell therapy biotech. Available at: https://www.fiercebiotech.com/biotech/astrazeneca-goes-vivo-penning-1b-deal-belgian-lentiviralvector-cell-therapy-biotech

Fierce Pharma (2021) AstraZeneca hits UK antitrust review with $39B Alexion buy after US FTC clearance. Available at: https://www.fiercepharma.com/pharma/astrazeneca-hits-u-k-antitrust-roadblock-39b-alexion-buy -despite-u-s-ftc-clearance

Fortune (2025) AstraZeneca to buy cell therapy biotech for up to $1 billion. Available at: https://fortune.com/europe/2025/03/17/astrazeneca-cell-therapy-biotech-esobiotec-1-billion-uk-p ascal-soriot/

Global Legal Post (2025) Cooley, Covington shepherd AstraZeneca's $1bn EsoBiotec acquisition. Available at: https://www.globallegalpost.com/news/cooley-covington-shepherd-astrazenecas-1bn-esobiotecacquisition-1021438879

Medpath (2025) AstraZeneca acquires EsoBiotec for $1 billion: revolutionary in vivo CAR-T technology to transform cancer treatment. Available at: https://trial.medpath.com/news/96b8b4a2083f9026/astrazeneca-acquires-esobiotec-for-1-billionrevolutionary-in-vivo-car-t-technology-to-transform-cancer-treatment

Medpath (2025) AstraZeneca reports strong 2024 performance with 21% revenue growth, sets ambitious 2025 pipeline goals. Available at: https://trial.medpath.com/news/4262d07cad88a586/astrazeneca-reports-robust-21-revenue-gro wth-in-2024-projects-strong-pipeline-momentum-for-2025

Nasdaq (2025) AZN to acquire EsoBiotec for $1B to develop in vivo cell therapies. Available at: https://www.nasdaq.com/articles/azn-acquire-esobiotec-1b-develop-vivo-cell-therapies

Nasdaq (2025) AstraZeneca rides oncology momentum with blockbuster and new drugs. Available at: https://www.nasdaq.com/articles/astrazeneca-rides-oncology-momentum-blockbuster-and-newdrugs

Nona Biosciences (2025) CAR-T cell therapy in 2025: breakthroughs, barriers, and the road ahead. Available at: https://nonabio.com/car-t-cell-therapy-in-2025-breakthroughs-barriers-and-the-road-ahead/

Pharma Now (2025) AstraZeneca acquires EsoBiotec for up to $1B. Available at: https://www.pharmanow.live/latest-news/astrazeneca-acquires-esobiotec-in-vivo-cell

PharmExec (2025) AstraZeneca acquires EsoBiotec; strikes deal with Alteogen to develop oncology therapies. Available at: https://www.pharmexec.com/view/astrazeneca-acquires-esobiotec-strikes-deal-alteogen-develo p-oncology-therapies

PitchBook (2026) EsoBiotec 2026 company profile. Available at: https://pitchbook.com/profiles/company/481993-48

ScienceDirect (2025) In vivo production of CAR T cell: opportunities and challenges, Genes and Diseases, 12(6). Available at: https://www.sciencedirect.com/science/article/pii/S2352304225001011

Tandfonline (2025) In vivo CAR-T cell therapy: new breakthroughs for cell-based tumor immunotherapy, Human Vaccines and Immunotherapeutics. Available at: https://www.tandfonline.com/doi/full/10.1080/21645515.2025.2558403

Targeted Oncology (2026) FDA clears IND of off-the-shelf in vivo CAR-T therapy for R/R myeloma. Available at: https://www.targetedonc.com/view/fda-clears-ind-of-off-the-shelf-in-vivo-car-t-therapy-for-r-r-mye loma

TIKR (2025) AstraZeneca's pipeline is deep, but analysts warn growth may normalize. Available at: https://www.tikr.com/blog/astrazenecas-pipeline-is-deep-but-analysts-warn-growth-may-normaliz e

Towards Healthcare (2025) Next gen CAR T therapy market trends and forecast 2025 to 2034. Available at: https://www.towardshealthcare.com/insights/next-gen-car-t-therapy-market-sizing